910447-82-4

Upstream product

• 910447-68-6 (2R,4R)-tert-butyl 4-(allyloxy)-2-((1S,2S)-2-(benzyloxycarbonylamino)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)pyrrolidine-1-carboxylate 
• 877078-49-4 (S)-4-benzyl-3-(3-(3,5-difluorophenyl)propanoyl)oxazolidin-2-one 
• 1345707-37-0 C₂₈H₄₂F₂N₂O₅Si 
• 877078-90-5 (2S,3S)-2-(3,5-difluorobenzyl)-3-((2R,4R)-4-(allyloxy)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-(tert-butyldimethylsilyloxy)propanoic acid 
• 877078-89-2 (2R,4R)-tert-butyl 2-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-1-(tert-butyldimethylsilyloxy)-3-oxopropyl)-4-(allyloxy)pyrrolidine-1-carboxylate 
• 877078-48-3 (2R,4R)-tert-butyl 2-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-1-hydroxy-3-oxopropyl)-4-(allyloxy)pyrrolidine-1-carboxylate 
• 877078-47-2 (2R,4R)-tert-butyl 4-(allyloxy)-2-formylpyrrolidine-1-carboxylate 

Downstream Products

• 910447-80-2 (2R,4R)-tert-butyl 2-((1S,2S)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)-2-(3-hydroxy-5-(2-oxopyrrolidin-1-yl)benzamido)propyl)-4-propoxypyrrolidine-1-carboxylate 
• 910447-83-5 (2R,4R)-tert-butyl 2-((1S,2S)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)-2-(3-(methoxycarbonyl)benzamido)propyl)-4-propoxypyrrolidine-1-carboxylate 
• 910447-98-2 C₄₄H₆₄F₂N₄O₇Si 
• 910447-74-4 (2R,4R)-tert-butyl 2-((1S,2S)-2-(3-bromo-5-(methoxycarbonyl)benzamido)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)-4-propoxypyrrolidine-1-carboxylate 
• 910447-97-1 (2R,4R)-tert-butyl 2-((1S,2S)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)-2-(3-((R)-2-(methoxymethyl)pyrrolidine-1-carbonyl)-5-(oxazol-2-yl)benzamido)propyl)-4-propoxypyrrolidine-1-carboxylate 
• 1345705-52-3 C₃₄H₄₇F₂N₃O₅ 
• 1345706-10-6 C₄₅H₆₉F₂N₃O₇Si 
• 1345705-50-1 C₃₂H₄₃F₂N₃O₅ 
• 1345706-08-2 C₄₃H₆₅F₂N₃O₇Si 
• 1345706-06-0 C₄₅H₆₉F₂N₃O₆Si 
• 1345705-59-0 C₂₇H₄₁F₂N₃O₅ 
• 1345706-18-4 C₃₈H₆₃F₂N₃O₇Si 
• 1345706-16-2 C₃₈H₆₃F₂N₃O₆Si 
• 1345705-55-6 C₂₆H₃₉F₂N₃O₄ 

Relevant academic research and scientific papers

Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE)

The synthesis, evaluation, and structure-activity relationships of a class of γ-lactam 1,3-diaminopropan-2-ol transition-state isostere inhibitors of BACE are discussed. Two strategies for optimizing lead compound 1a are presented. Reducing the overall size of the inhibitors resulted in the identification of γ-lactam 1i, whereas the introduction of conformational constraint on the prime-side of the inhibitor generated compounds such as the 3-hydroxypyrrolidine inhibitor 28n. The full in vivo profile of 1i in rats and 28n in Tg 2576 mice is presented.

NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS

There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.